A5081242987- Tuberculosis Research and Epidemiology
- HIV/AIDS Impact and Responses
- Pneumonia and Respiratory Infections
- Pneumocystis jirovecii pneumonia detection and treatment
- Healthcare Systems and Reforms
- Global Maternal and Child Health
- Diagnosis and treatment of tuberculosis
- Global Health and Epidemiology
- Mycobacterium research and diagnosis
- Global Health and Surgery
- HIV/AIDS Research and Interventions
- Infectious Diseases and Tuberculosis
- Health Systems, Economic Evaluations, Quality of Life
- Adolescent Sexual and Reproductive Health
- Child Nutrition and Water Access
- Global Public Health Policies and Epidemiology
- HIV/AIDS drug development and treatment
- Chronic Disease Management Strategies
- Global Health Care Issues
- Human Rights and Development
- COVID-19 Clinical Research Studies
- HIV, Drug Use, Sexual Risk
- Community Development and Social Impact
- Pharmaceutical Economics and Policy
- HIV Research and Treatment
World Health Organization
2015-2024
Boston University
2023
Institute for Health Metrics and Evaluation
2020
Center for Surveillance, Epidemiology, and Laboratory Services
2020
World Health Organization - Pakistan
2004-2018
London School of Hygiene & Tropical Medicine
2002-2018
University of London
2018
Rwanda Biomedical Center
2016
Ministry of Health
2016
World Health Organization Regional Office for the Eastern Mediterranean
2013
Objective To present a global update of drug-resistant tuberculosis (TB) and explore trends in 1994-2010.Methods Data on drug resistance among new previously treated TB patients, as reported by countries to the World Health Organization, were analysed.Such data are collected through surveys representative sample patients or surveillance systems based routine susceptibility testing.Associations between multidrug-resistant (MDR-TB) human immunodeficiency virus (HIV) infection sex explored...
Worldwide, tuberculosis (TB) is the leading cause of death from a single infectious disease agent (1) and among persons living with human immunodeficiency virus (HIV) infection, accounting for approximately 40% deaths in this population (2). The United Nations' (UN) Sustainable Development Goals (3) World Health Organization's (WHO's) End TB Strategy (4) have defined ambitious targets 2020-2035, including 35% reduction absolute number 20% incidence by 2020, compared 2015 (4). Since 2000, WHO...
In many countries, national tuberculosis (TB) prevalence surveys are the only way to reliably measure burden of TB disease and monitor trends. They can also provide evidence about current performance care control how this could be improved. We developed an inventory Asian from 1953 2012 then compiled analysed a standard set data for all implemented between 1990 (the baseline year 2015 global targets) 2012.There were 21 in 12 countries 2012; published results available 18. The participation...
Worldwide, tuberculosis (TB) is the leading cause of death from a single infectious disease and especially deadly for persons living with human immunodeficiency virus (HIV) infection. Although recent trends point to modest progress towards global TB targets, more focus commitment needed find, cure, prevent TB.
Although tuberculosis (TB) is curable and preventable, in 2019, TB remained the leading cause of death from a single infectious agent worldwide among persons living with HIV infection (1). The World Health Organization's (WHO's) End Strategy set ambitious targets for 2020, including 20% reduction incidence 35% number deaths compared 2015, as well zero TB-affected households facing catastrophic costs (defined exceeding annual household income) (2). In addition, during 2018 United Nations...
ultidrug-resistant (MDR) tuberculosis is defined as disease caused by strains of Mycobacterium that are at least resistant to treatment with isoniazid and rifampicin; extensively drug-resistant (XDR) refers multidrug-resistant also any fluoroquinolone the injectable drugs used in second-line anti-tuberculosis (amikacin, capreomycin, kanamycin).MDR XDR serious threats progress has been made control worldwide over past decade. 1,2 In 2008, an estimated 440,000 cases MDR emerged globally....
With 1.4 million deaths in 2011 and 8.7 new cases, tuberculosis (TB) disease remains a global scourge. Global targets for reductions the epidemiological burden of TB have been set 2015 2050 within context Millennium Development Goals (MDGs) by Stop Partnership. Achieving these is focus national international efforts control, demonstrating whether or not they are achieved major importance to guide future sustainable investments. This paper discusses methods used estimate TB; estimates...
Abstract Objective and Methods In many countries, national tuberculosis (TB) prevalence surveys are the only way to reliably measure burden of TB disease monitor trends. They can also provide evidence about current performance care control how this could be improved. We developed an inventory Asian from 1953 2012 then compiled analysed a standard set data for all implemented between 1990 (the baseline year 2015 global targets) 2012. Results There were 21 in 12 countries 2012; published...
BackgroundPyrazinamide and fluoroquinolones are essential antituberculosis drugs in new rifampicin-sparing regimens. However, little information about the extent of resistance to these at population level is available.MethodsIn a molecular epidemiology analysis, we used population-based surveys from Azerbaijan, Bangladesh, Belarus, Pakistan, South Africa investigate pyrazinamide among patients with tuberculosis. Resistance was assessed by gene sequencing detection resistance-conferring...
BackgroundThe End TB Strategy and the Sustainable Development Goals (SDGs) are intimately linked by their common targets approaches. SDG 1 aims to end extreme poverty expand social protection coverage 2030. Achievement of is likely affect tuberculosis epidemic through a range pathways. We estimate reduction in global incidence that could be obtained reaching 1.MethodsWe developed conceptual framework linking key indicators progress via well described risk factor pathways populated it with...
In many countries, regular monitoring of the emergence resistance to anti-tuberculosis drugs is hampered by limitations phenotypic testing for drug susceptibility. We therefore evaluated use genetic sequencing surveillance in tuberculosis.Population-level surveys were done hospitals and clinics seven countries (Azerbaijan, Bangladesh, Belarus, Pakistan, Philippines, South Africa, Ukraine) evaluate estimate Mycobacterium tuberculosis isolates rifampicin, isoniazid, ofloxacin, moxifloxacin,...